reports
Lifecore Biomedical to be Added to Nasdaq Biotech Index
Lifecore Biomedical to be Added to Nasdaq Biotech Index CHASKA, Minn., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it has been notified by Nasdaq that the company’s stock is expected to be added to the Nasdaq Biotech Index (NASDAQ: NBI) as part of the annual reconstitution of the 2025 Nasdaq indexes. Lifecore’s inclusion in the Nasdaq Biotech Index will be effective prior to market open on Monday, December 22, 2025. The Nasdaq Biotechnology Index ...
Lifecore Biomedical Signs CDMO Master Services Agreement with New Larg...
Lifecore Biomedical Signs CDMO Master Services Agreement with New Large Multinational Pharmaceutical Customer Agreement Calls for Development Services and Tech Transfer in Preparation for Commercial Manufacturing of Injectable Pharmaceutical Product Partner’s Program Size Positions it to Become a Top Five Commercial Customer for Lifecore CHASKA, Minn., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it has signed a CDMO master services agreement wit...
Lifecore Biomedical to Participate at 44th Annual J.P. Morgan Healthca...
Lifecore Biomedical to Participate at 44th Annual J.P. Morgan Healthcare Conference CHASKA, Minn., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate at the 44th Annual J.P. Morgan Healthcare Conference. The conference will take place January 12-15, 2026, in San Francisco, California. Details regarding Lifecore’s participation are as follows: 44th Annual J.P. Morgan Healthcare ConferenceDetails: Lifecore management, includin...
Dorchester Minerals, L.P. Announces the Retirement of Mr. William Case...
Dorchester Minerals, L.P. Announces the Retirement of Mr. William Casey McManemin from the Board of Managers; Appointments of Mr. Robert C. Vaughn as Interim Chairman and Mr. Albert G. Nance III to the Board of Managers DALLAS, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Dorchester Minerals, L.P. (the “Partnership”) (NASDAQ-DMLP) announces the retirement of Mr. William Casey McManemin from the Board of Managers of Dorchester Minerals Management GP LLC, the general partner of the Partnership’s general partner (the “Board”), effective December 31, 2025. Mr. McManemin previously led the Partnershi...
Dorchester Minerals Lp: 1 director
A director at Dorchester Minerals Lp bought 5,000 shares at 21.965USD and the significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years...
Lifecore Biomedical to Participate in Upcoming Investor Conferences
Lifecore Biomedical to Participate in Upcoming Investor Conferences CHASKA, Minn, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate in two upcoming investor conferences. Details regarding Lifecore’s participation are as follows: Jefferies 2025 Global Healthcare Conference – London Details: Paul Josephs, Lifecore’s president and chief executive officer, will deliver a corporate presentation and Lifecore management will parti...
Lifecore Biomedical Reports Financial Results for the Three Months End...
Lifecore Biomedical Reports Financial Results for the Three Months Ended September 30, 2025, and Provides Corporate Update -- Recorded $31.1 Million in Revenue During the Three Months Ended September 30, 2025, Representing a 26% Increase From Comparable Period of 2024 -- -- Multiple New Programs Signed with New Customers -- -- Continued Improvements in Efficiency and Productivity Across the Organization -- Conference Call Today at 4:30pm ET CHASKA, Minn., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development an...
Dorchester Minerals, L.P. Announces Third Quarter Results
Dorchester Minerals, L.P. Announces Third Quarter Results DALLAS, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Dorchester Minerals, L.P. (the “Partnership”) (NASDAQ-DMLP) announced today the Partnership’s net income for the quarter ended September 30, 2025 of $11,173,000, or $0.23 per common unit. A comparison of the Partnership’s consolidated results for the quarters ended September 30, 2025 and 2024 are set forth below: Three Months Ended Nine Months Ended September 30, September 30, 2025 2024 2025 2024Operating Revenues$35,416,000 $53,472,000 $110,975,000 $121,811,000Net Income$11,173,000 $36,4...
Dorchester Minerals, L.P. Announces the Passing of C.W. “Bill” Russell
Dorchester Minerals, L.P. Announces the Passing of C.W. “Bill” Russell DALLAS, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Dorchester Minerals, L.P. (the “Partnership”) (NASDAQ-DMLP) mourns the passing of C.W. “Bill” Russell, a dedicated member of our Board of Managers and Advisory Committee since 2004, and Chairman of the Audit Committee. Bill’s distinguished career in energy taxation, including his leadership at KPMG where he served as National Director, Technical Tax Services – Energy and Chairman of the KMPG International Petroleum Group, brought invaluable expertise to the Partn...
Lifecore Biomedical to Report Financial Results for the Three Months E...
Lifecore Biomedical to Report Financial Results for the Three Months Ended September 30, 2025, on November 6, 2025 Webcast Scheduled for Thursday, November 6 at 4:30 p.m. Eastern CHASKA, Minn., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it will report financial results for the three months ended September 30, 2025, on Thursday, November 6, 2025, after market close. At 4:30 p.m. Eastern Time that day, members of Lifecore’s senior management team ...
Lifecore Biomedical Selected as New Commercial Manufacturing Partner b...
Lifecore Biomedical Selected as New Commercial Manufacturing Partner by Leading Global Pharmaceutical Company Lifecore to Execute Commercial Site Transfer and Become New Supplier of Choice for Leading Commercial Injectable Pharmaceutical Product Represents Second Agreement Signed with Same Major Multinational Organization in Recent Months Separate Pre-Clinical Formulation Development Agreement Signed with New Early-Stage Biotech Customer CHASKA, Minn., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manuf...
Lifecore and PolyPeptide Announce Collaboration Intended to Offer End-...
Lifecore and PolyPeptide Announce Collaboration Intended to Offer End-to-End Peptide Manufacturing Solution for U.S. Market CHASKA, Minn. and TORRANCE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), and PolyPeptide Laboratories, Inc. (“PolyPeptide”), a global leader in peptide contract development and manufacturing, today announced the signing of a collaboration agreement aimed at providing an integrated, end-to-end solution for peptide-based pharmaceutical custom...
Dorchester Minerals, L.P. Announces Its Third Quarter Distribution
Dorchester Minerals, L.P. Announces Its Third Quarter Distribution DALLAS, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Dorchester Minerals, L.P. (NASDAQ:DMLP) announced today the Partnership’s third quarter 2025 cash distribution. The distribution of $0.689883 per common unit represents activity for the three-month period ended September 30, 2025 and is payable on November 13, 2025 to common unitholders of record as of November 3, 2025. Cash receipts attributable to the Partnership’s Royalty Properties during the third quarter totaled approximately $33.0 million. Approximately 70% of these receipt...
Lifecore Biomedical to Participate at Upcoming Industry Conferences an...
Lifecore Biomedical to Participate at Upcoming Industry Conferences and Events CHASKA, Minn., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate at three upcoming industry events. Details of the company’s activities at these events are as follows: 15th Annual Partnership Opportunities in Drug Development (PODD)Conference Dates/Location: October 27-28, 2025, in Boston, MADetails: Ryan Swanson, Ph.D., Lifecore’s director of pro...
Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(...
Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) CHASKA, Minn., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”) a fully integrated contract development and manufacturing organization (“CDMO”), today announced that on September 22, 2025, the Lifecore compensation committee approved the grant under Lifecore’s Equity Inducement Plan, as amended (the “Inducement Plan”) of a restricted stock unit (“RSU”) award with respect to 15,000 shares of its common stock and stock options for 30,000 shares of common stock to a newly hired em...
Lifecore Biomedical to Participate at 24th Annual Contract Pharma Cont...
Lifecore Biomedical to Participate at 24th Annual Contract Pharma Contracting and Outsourcing Conference CHASKA, Minn., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate at the 24th Annual Contract Pharma Contracting and Outsourcing Conference. Recognized as one of the top annual events for pharmaceutical outsourcing and contract manufacturing, the Contract Pharma conference will take place September 18-19, 2025, in New Brun...
Dorchester Minerals, L.P. Announces Acquisition of Mineral Interests
Dorchester Minerals, L.P. Announces Acquisition of Mineral Interests DALLAS, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Dorchester Minerals, L.P. (the “Partnership”) (NASDAQ-DMLP) announced today it completed an acquisition of mineral interests totaling approximately 3,050 net royalty acres located in Adams County, Colorado. The transaction was structured as a non-taxable contribution and exchange. The contributing entities conveyed their interests to the Partnership in exchange for 915,694 common units representing limited partnership interests in Dorchester Minerals, L.P. Dorchester Minerals...
Lifecore Biomedical to Participate in Upcoming Investor Conferences
Lifecore Biomedical to Participate in Upcoming Investor Conferences CHASKA, Minn., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate in multiple upcoming investor conferences. Details regarding Lifecore’s participation are as follows: Morgan Stanley 23rd Annual Global Healthcare ConferenceDetails: Lifecore management will participate in a fireside chat and in investor meetingsConference Dates: September 8-10, 2025Fireside...
Lifecore Biomedical Reports Fourth Quarter and Fiscal Year 2025 Financ...
Lifecore Biomedical Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update -- Recorded $128.9 Million in Fiscal 2025 Revenue, Meeting Full-Year Guidance; Maintains Commitment to Mid-Term Outlook -- -- Nine New Programs Signed with New Customers During Fiscal 2025, Reflecting Growth into Modalities Beyond the Company's Traditional Area of Strength in Ophthalmic Therapeutics -- -- Improved Efficiency and Productivity Across the Organization -- Conference Call Today at 4:30pm ET CHASKA, Minn., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, In...
Dorchester Minerals, L.P. Announces Second Quarter Results
Dorchester Minerals, L.P. Announces Second Quarter Results DALLAS, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Dorchester Minerals, L.P. (the “Partnership”) (NASDAQ-DMLP) announced today the Partnership’s net income for the quarter ended June 30, 2025 of $12,347,000, or $0.25 per common unit. A comparison of the Partnership’s consolidated results for the quarters ended June 30, 2025 and 2024 are set forth below: Three Months Ended Six Months Ended June 30, June 30, 2025 2024 2025 2024Operating Revenues$32,395,000 $37,360,000 $75,559,000 $68,339,000Net Income$12,347,000 $23,628,000 $29,989,00...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.